ForPatients
by Roche

Rheumatoid Arthritis

Tocilizumab Real-Life Human Factors (RLHFs) Validation Study

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT02682823 WA29917

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study is designed to evaluate RLHFs concerning administration of the tocilizumab autoinjector AI-1000 G2 in adults with rheumatoid arthritis (RA) who have been receiving subcutaneous (SC) tocilizumab using the commercially available prefilled syringe and needle safety device (PFS-NSD). The study will enroll participants with RA, a subset of whom will be assigned to perform self-injection with the AI-1000 G2. Enrolled caregivers (CGs) and healthcare professionals (HCPs) will administer the AI-1000 G2 injection to the remaining study participants.

Hoffmann-La Roche
Sponsor

Phase 4
Phase

NCT02682823 WA29917
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 18 Years	No